Measuring attractiveness for abuse of prescription opioids.
about
Using Social Listening Data to Monitor Misuse and Nonmedical Use of Bupropion: A Content Analysis.Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.Toward a systematic approach to opioid rotation.The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitabilityDesigning opioids that deter abuseRisk based in vitro performance assessment of extended release abuse deterrent formulationsAssessment of a formulation designed to be crush-resistant in prescription opioid abusers.A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers.A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of OxycodoneUpdate on prescription extended-release opioids and appropriate patient selection.Randomized, double-blind, placebo-controlled and active-controlled study to assess the relative abuse potential of oxycodone HCl-niacin tablets compared with oxycodone alone in nondependent, recreational opioid users.Primary care considerations of the pharmacokinetics and clinical use of extended-release opioids in treating patients with chronic noncancer pain.Characterization of prescription opioid abuse in the United States: focus on route of administration.Comparison of subjective effects of extended-release versus immediate-release oxycodone/acetaminophen tablets in healthy nondependent recreational users of prescription opioids: a randomized trial.Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.[Misuse of opioid analgesics. An internet analysis].Correlation of Subjective Effects with Systemic Opioid Exposure from Fixed-Dose Combinations of Oxycodone/Acetaminophen in Recreational Users of Prescription Drugs.Safety and Tolerability of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets: Analysis of 11 Clinical Trials.Validity testing of patient objections to acceptance of tamper-resistant opioid formulations.Designing a tool allowing for a standardized assessment of resistance to drug diversion.Abuse-deterrent formulations of opioid analgesics.Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.Relative Abuse of Crush-Resistant Prescription Opioid Tablets via Alternative Oral Modes of Administration.Human abuse potential of immediate-release/extended-release versus immediate-release hydrocodone bitartrate/acetaminophen: a randomized controlled trial in recreational users of prescription opioids.A history of being prescribed controlled substances and risk of drug overdose death.Attenuating the Agent: Reducing Opioid “Virulence”A Brief Survey to Characterize Oxycodone Abuse Patterns in Adolescents Enrolled in Two Substance Abuse Recovery High Schools
P2860
Q31158757-E97228EF-6F62-4D18-822F-D87C378323AAQ33633386-E43B215D-314E-46FF-ACE3-C2194050F46FQ34394425-0BC0A75B-3BCD-4328-B6FD-BDBD08877C02Q35209803-FDA2995F-2323-41F2-8FB5-8C53745C2256Q36415568-C9ADF16C-33C7-4F15-A8F0-BBB88177ABC6Q36586105-2CAF94A9-4D08-4DBC-A953-000AEC82689EQ36845718-D294A8BC-900B-4E30-AA63-B351E719C0B5Q36878938-4CD21743-12BF-43BF-B1B3-2F1F28D1011CQ36972164-0356A918-A967-4DB2-B5F0-ED4E4D89A27EQ37053718-3B13873E-C9C0-4755-9B65-8BD6BBF5B82CQ37457193-98F1ACC2-A3BE-47B4-80D4-5BDC7AD722A5Q38079923-9AF11D2A-2786-48A9-B659-99162A302896Q38106987-216ABD5A-2CCF-4E98-8687-A24F7234A867Q38241632-13A38A5A-7252-4FFC-9EE3-04DA01032D6CQ38632934-C94D00FB-E74C-41EA-BB44-E10BC334DAC6Q39202730-506BD3B6-B6CA-42B1-9949-99E57ECCE82CQ40610091-6D01512A-3EBA-4DE9-8323-D61126239F04Q40619029-D3AF9BFF-CACB-4877-8462-E8049759D67FQ40844854-380796F2-B1F7-4B22-AD9B-DE293F701B49Q43317466-93176AAA-BB6A-405C-99E2-5AA4855DC2BEQ43976503-4EC9216B-CC7E-4BF4-8406-3446D84D7CBCQ44184161-965E5AD8-2E45-4CC5-A325-BCE3123A8F82Q44349641-C06E6F69-F341-4633-8861-A2F02A2930A6Q53638999-310C9E00-97ED-4BC5-B809-B4AE73FBC62AQ53690475-037C364A-13E4-479A-872C-6F7B822B6A61Q57462886-9817FEA2-F7E1-4B71-8475-6B1090468B26Q58243890-F7450D86-DF59-4DBE-B3A2-E95C1ADDD195
P2860
Measuring attractiveness for abuse of prescription opioids.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Measuring attractiveness for abuse of prescription opioids.
@en
Measuring attractiveness for abuse of prescription opioids.
@nl
type
label
Measuring attractiveness for abuse of prescription opioids.
@en
Measuring attractiveness for abuse of prescription opioids.
@nl
prefLabel
Measuring attractiveness for abuse of prescription opioids.
@en
Measuring attractiveness for abuse of prescription opioids.
@nl
P2093
P1433
P1476
Measuring attractiveness for abuse of prescription opioids.
@en
P2093
Alan Chang
Christine Benoit
Kathrine C Fernandez
Nathaniel Katz
Ryan Black
P356
10.1111/J.1526-4637.2009.00736.X
P577
2009-11-25T00:00:00Z